The U.S. Food and Drug Administration announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

Entest BioMedical Inc. (OTCBB: ENTB) announced it has obtained its first tumor specimen, a canine parathyroid tumor to be utilized in the development of Entest’s immunotherapeutic cancer vaccine. According to Dr. Steven Josephs, lead cancer researcher for Entest, “Stem cells derived from tumors appear to be key components for creating an immunotherapeutic tumor vaccine. Inducing [...]

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology – Head and Neck Surgery.

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body’s immune system.
The University of Michigan and Veterans Affairs research adds to growing awareness of the immune system’s role in COPD, a serious, progressive lung disease that affects more than 12 million Americans [...]

Novartis announced that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).